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Introduction: Triple-negative breast cancer (TNBC) is a heterogeneous group of tumours in which chemotherapy,
the current mainstay of systemic treatment, is often initially beneficial but with a high risk of relapse and metastasis.
There is currently no means of predicting which TNBC will relapse. We tested the hypothesis that the biological
properties of normal stem cells are re-activated in tumour metastasis and that, therefore, the activation of normal
mammary stem cell-associated gene sets in primary TNBC would be highly prognostic for relapse and metastasis.
Methods: Mammary basal stem and myoepithelial cells were isolated by flow cytometry and tested in low-dose
transplant assays. Gene expression microarrays were used to establish expression profiles of the stem and
myoepithelial populations; these were compared to each other and to our previously established mammary
epithelial gene expression profiles. Stem cell genes were classified by Gene Ontology (GO) analysis and the expression
of a subset analysed in the stem cell population at single cell resolution. Activation of stem cell genes was interrogated
across different breast cancer cohorts and within specific subtypes and tested for clinical prognostic power.
Results: A set of 323 genes was identified that was expressed significantly more highly in the purified basal stem cells
compared to all other cells of the mammary epithelium. A total of 109 out of 323 genes had been associated with
stem cell features in at least one other study in addition to our own, providing further support for their involvement in
the biology of this cell type. GO analysis demonstrated an enrichment of these genes for an association with cell
migration, cytoskeletal regulation and tissue morphogenesis, consistent with a role in invasion and metastasis. Single
cell resolution analysis showed that individual cells co-expressed both epithelial- and mesenchymal-associated
genes/proteins. Most strikingly, we demonstrated that strong activity of this stem cell gene set in TNBCs identified
those tumours most likely to rapidly progress to metastasis.
Conclusions: Our findings support the hypothesis that the biological properties of normal stem cells are drivers of
metastasis and that these properties can be used to stratify patients with a highly heterogeneous disease such as
TNBC.Introduction
Breast cancer is a highly heterogeneous disease broadly
classified on the basis of clinical parameters such as size,
grade and node status, as well as histopathological
criteria, primarily expression of estrogen receptor (ER),
progesterone receptor (PR), and human epidermal
growth factor receptor 2 (HER2) [1]. While defined
targeted therapeutic strategies have been developed for* Correspondence: SmalleyMJ@Cardiff.ac.uk
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unless otherwise stated.patients with ER+/PR+ and HER2+ diseases, chemother-
apy is currently the mainstay of systemic treatment for
triple-negative (ER−/PR−/HER2−) breast cancer (TNBC)
patients, which represents approximately 20% of all
breast cancers [2]. Clinically, TNBC encompasses a
heterogeneous group of aggressive tumours with poor
prognosis [1,3-7], partly due to high recurrence within
the first years and limited targeted therapy options. Al-
though chemotherapy is often initially beneficial in
these tumours, especially in the neoadjuvant setting,
many TNBCs have a high risk of relapse [8]. Since
there is currently no means of predicting which TNBC
will relapse, identification of subpopulations of TNBCThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ment of these breast cancer patients.
Strong evidence is emerging supporting the hypothesis
that cancer stem cells with similar features to normal
tissue stem cells are resistant to standard chemotherapy
and drive tumour regrowth after therapy finishes [9].
We hypothesised that biological properties of normal
stem cells are reactivated in tumour cells to facilitate
metastasis. Genes expressed in stem cells of the normal
mammary gland might therefore carry prognostic infor-
mation for relapse and metastasis in breast cancer. How-
ever, the development of such gene sets depends on the
ability to isolate highly pure stem cells for analysis.
The mammary epithelium consists of two main layers,
the luminal and basal layers. The luminal layer consists
of ER- cells (mainly proliferative progenitors) and ER+
cells (mainly non-proliferative differentiated cells). The
basal layer consists of myoepithelial cells (MYOs) and
mammary stem cells (MaSCs), the latter characterised
by their robust outgrowth activity in the cleared fat pad
transplant assay. The relationship between these popula-
tions is summarised in Additional file 1A. Previous
studies have analysed total basal breast epithelial cells,
without further purification of the minority stem cell
fraction [10] or used a dye label-retention strategy to
identify asymmetrically dividing cells (putative stem
cells) in non-adherent mammosphere cultures [11]. Only
one previous study has attempted to freshly purify basal
stem cells and compare their gene expression profile to
MYOs [12]; however, that study identified only four
genes expressed >2-fold more highly in stem cells com-
pared to MYOs, and none of these achieved statistical
significance. Here, we have defined the first gene signa-
ture specific for highly purified, freshly isolated MaSCs
and further enriched the stem cell specificity by exclud-
ing basal-associated genes common to both the stem
and myoepithelial populations. Pathway analysis revealed
that this signature was enriched in genes associated with
cell migration, adhesion and tissue morphogenesis.
Single cell resolution gene expression analysis showed
that the stem cell population included cells that
expressed both epithelial- and mesenchymal-associated
genes. Strikingly, when the expression of the stem cell
gene signature was interrogated in two large independ-
ent TNBC cohorts, tumours with an activated stem cell
signature showed a higher propensity to relapse in the
first years after diagnosis in comparison to TNBC with
lower activation scores for the stem cell gene signature.
In contrast, in three large independent ER+ breast can-
cer data sets, an activated stem cell signature identified
tumours least likely to metastasise. The prognostic
power of the stem cell gene signature when applied to
expression profiling of total tumour material implies
that in poor prognosis TNBC the cancer stem cell-likegenetic programme is not restricted to a minority cell
population but rather is driving the behaviour of the
bulk of tumour cells.
Our findings show that the biology of normal MaSCs,
as reflected in their gene expression profiles, is highly
relevant for understanding the drivers of aggressive
disease in TNBC.
Methods
Preparation of mammary epithelial cells for flow
cytometry
All animal work was carried out under UK Home Office
project and personal licences following local ethical ap-
proval by the Institute of Cancer Research Animal Ethics
Committee and in accordance with local and national
guidelines. Single cells were prepared from fourth mam-
mary fat pads of 8- to 10-week-old virgin female FVB mice
as described [13] and stained with anti-CD24-FITC, anti-
Sca-1-APC, anti-CD45-PE-Cy7, anti-CD49f-PE-Cy5 and
anti-c-Kit-PE. Mammary epithelial cell subpopulations
were defined as shown in Figure 1 and Additional file 1.
Cleared mammary fat pad transplantations
Transplantation of primary mouse mammary epithelial
cells was carried out as described [13]. Sorted cells were
transplanted at 200 cells per fat pad into the cleared fat
pads of 21-day-old syngeneic FVB mice over three inde-
pendent sort and transplant sessions for each popula-
tion. Positive control transplants of total basal cells at
20,000 cells per fat pad were also included in each ses-
sion. Fat pads were analysed by whole-mounting eight
weeks after transplantation.
RNA isolations and gene expression analysis by
quantitative real-time rtPCR (qrtPCR)
Freshly sorted primary cells were lysed in RLT buffer
(Qiagen, Crawley, West Sussex, UK) and stored at −80°C.
Total RNA was extracted using an RNeasy MiniElute or
MicroElute Kit (Qiagen), according to the manufacturers’
instructions. qrtPCR reactions were performed as previ-
ously described use Taqman probes (see Additional file 2)
[14]. Results either were calculated using the ΔΔCt
method and expressed as the mean fold gene expression
difference in three independently isolated cell preparations
over a comparator sample with 95% confidence intervals,
or, for single cell experiments, presented as raw 1/Ct
values.
Immunofluorescent staining of cells sorted on to slides
Samples of 50 to 200 cells were sorted directly on to
poly-L-lysine-coated slides, air dried, and stored at −20°C.
The cells were fixed in 1:1 methanol acetone for 5 minutes
at −20°C (keratin 14 (K14)/keratin 18 (K18)) or 4% para-
formaldehyde (ERα and keratin 15 (K15)/vimentin (Vim))
Figure 1 Isolation of high-purity basal mammary stem cells. (A, B). Flow cytometry of mouse mammary epithelial cells isolated from 8- to
10-week-old virgin FVB mice and stained with antibodies against CD24, Sca-1, CD49f and c-Kit. (A) Isolation of the luminal ER- progenitor (Gate I)
and luminal ER+ cell populations (Gate II) on the basis of CD24 and Sca-1 expression followed by c-Kit as previously described [13]. (B) Isolation
of basal myoepithelial (MYO; Gate III) and mammary stem cells (MaSCs; Gate IV), from the same sort data as in (A), on the basis of CD24 and
CD49f expression followed by c-Kit as previously described [13]. Only epithelial cell data is shown. For the full gating hierarchy see Additional
file 1. (C) qrtPCR gene expression analysis of mammary epithelial lineage-specific genes. Data expressed as mean fold expression (±95%
confidence intervals) over comparator population (luminal ER- cells) in three independent isolates of each cell population. Statistical significance
was determined according to [74]. **P <0.01 relative to comparator. ‘Typical expression’ indicates the populations expected to have the highest
levels of expression of the genes based on previous findings [13]. §Dmbt1 expression was undetectable in all isolates of MaSC and MYO
populations. (D) Results of low-dose transplantation of mammary subpopulations into cleared fat pads. The number of successful outgrowths,
the total number of fat pads transplanted and the extent each outgrowth filled the fat pads, as indicated by the pie chart symbols, are shown. ER,
estrogen receptor; qrtPCR, quantitative real-time rtPCR.
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rinsed twice in phosphate-buffered saline (PBS) and per-
meabilised by incubation with 0.5% PBS/TritonX-100 for
10 minutes. Slides were washed twice in PBS then once in
immunofluorescence buffer (IFF; 1% w/v bovine serum al-
bumen (Invitrogen, Life Technologies, Paisley UK), 2% v/v
foetal calf serum (FCS, Invitrogen) in PBS) before incuba-
tion with primary antibodies (mouse anti-K15 clone
LHK15, 1:200 dilution, #ab80522 Abcam, Cambridge, UK;
rabbit anti-vimentin EPR3776, 1:500 dilution, #2707-1
Epitomics/Abcam; mouse anti-K14 clone LLOO2, 0.26
ug/ml, #ab7800 Abcam; mouse anti-K18 clone Ks18.04,
1:5 dilution, #61028 Progen Biotechnik, Heidelberg,
Germany; mouse anti-ERα clone ID5, 9.9 ug/ml, #M7047
Dako, Cambridge, UK) for 60 minutes at RT. Cells were
washed with PBS three times for 5 minutes each before
the Alexa-conjugated secondary antibodies (Alexa-488
and/or Alexa-555, each at 1:500, Invitrogen) were applied
for 60 minutes at RT. The slides were washed three times
for 5 minutes each in 0.01% PBS/DAPI, rinsed in water
and mounted and coverslipped with Vectashield (Vector
Laboratories, Peterborough, UK). Images were captured
using a Leica TCS-SP2 microscope with images collected
in three channels using Leica LCS software (Leica Micro-
systems, Wetzlar, Germany). ‘No First Antibody’ controls
were used to set PMT levels. Controls using only one first
antibody with both second antibodies were used to con-
firm lack of cross-reactivity of second antibody staining.
Immunocytochemical staining of mammary tissue
Paraffin-embedded tissue sections on poly-L-lysine-coated
slides were dewaxed in xylene (2 × 5 minutes) and rehy-
drated by washing in decreasing concentrations of etha-
nol: 2 × 3 minutes in 100% ethanol, 1 × 3 minutes 95%
ethanol and 1 × 3 minutes 75% ethanol. Antigen retrieval
was carried out by incubating the slides in preheated
citrate buffer (99.9°C, pH6; Thermo Fisher Scientific,
Loughborough, UK) for 20 minutes. Slides were then
left to cool for 30 minutes at RT. Slides were then in-
cubated with a peroxidase-blocking solution (Vim and
smooth muscle actin (SMA): 3% hydrogen peroxide,
CK14: 1 in 60 hydrogen peroxide v/v in methanol) for
10 minutes at RT, followed by three 5-minute washes
in washing buffer (Vim and CK14: 0.1% Tween in
Tris-buffered saline (TBS), SMA: PBS). The slides
were blocked with serum diluted in wash buffer
(Vim and SMA: normal goat serum, CK14: MOM
diluents, MOM kit, Vector Laboratories) for 45 mi-
nutes at RT. The serum block was removed and
slides were incubated immediately with the primary
antibody in serum/wash buffer overnight at 4°C. Vim
was detected using a goat polyclonal antibody (Santa
Cruz SC-7557, Santa Cruz Biotechnology, Santa Cruz,
CA, USA) at 1:300 dilution, SMA using a rabbit polyclonal(Abcam, #ab5694), and CK14 using a mouse monoclonal
antibody (Abcam, #ab7800). Unbound primary antibody
was removed by three 5-minute washes in wash buffer
and then the slides were then incubated for 1 hour at RT
with the secondary antibody in serum/wash buffer (Vim
and SMA: anti-rabbit biotinylated (Dako), CK14: anti-
mouse (MOM kit)). The positive signal was amplified by
incubating the slides for 30 minutes at room temperature
with the Avidin-Biotin Complex (ABC) kit (Vector
Laboratories), made up 30 minutes before it was applied,
then positivity was visualised by incubating the slides with
the DAB+ Chromogen reagent (EnVision™ kit, Dako). The
reagent was applied to the slides for 5 minutes, and then
removed by three washes with wash buffer. The slides
were counterstained in haematoxylin for 60 seconds,
followed by a wash in running water for 5 minutes. The
slides were dehydrated by washing in increasing concen-
trations of alcohol, placed in xylene for 2 × 5 minutes and
then mounted with a glass coverslip.
Affymetrix transcriptome analysis
RNA was isolated from three independent myoepithelial
and seven independent MaSC isolations. Samples were
submitted to the UCL Genomics facility (UCL Institute
of Child Health, London, UK) for amplification and hy-
bridisation to the Mouse Genome 430 2.0 Affymetrix
array (Affymetrix, High Wycombe, UK). Total RNA was
amplified using the NuGEN Ovation Pico WTA System
(Nugen, Leek, The Netherlands). Resulting double-stranded
cDNA was fragmented and labelled using the Affymetrix
Genechip WT Terminal Labelling kit. Affymetrix Mouse
Genome 430 2.0 chip arrays were hybridised and scanned
according to manufacturer’s instructions.
Expression data were normalised and summarised by
robust multi-array analysis (RMA) using the Affymetrix
package in R. Probesets mapping to unknown or mul-
tiple genes were removed from analysis. Probesets were
used for two class unpaired comparison using signifi-
cance analysis of microarray (SAM) R package [15],
genes that were enriched or depleted in the MaSC popu-
lation compared to the myoepithelial population were
determined by a local false discovery rate (FDR) <5%.
For comparison to data from Kendrick et al. [16], all
CEL files were RMA normalised together and two class
unpaired SAM using a local FDR of 5% was applied to
each population compared to the MaSC population. Pro-
besets were also used for a multiclass SAM [16] to de-
termine if their mean expression was different across the
four mammary epithelial cell subpopulations. Hierarch-
ical cluster based on Pearson’s correlation with average
linkage was performed in the software package Cladist
of the ROCK database [17,18]. Pathway analysis was per-
formed using the DAVID KEGG pathway analysis tool
and the ROCK pathway analysis tool [17-20]. All
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gene sets with an enrichment score of FDR of 5% were
considered significantly enriched. Overlaps between gene
sets were visualised using VENNY [21]. MIAME-compliant
data have been uploaded to ArrayExpress with the acces-
sion number E-MTAB-2741.
Single cell resolution gene expression analysis
Single MaSCs were subjected to PCR essentially as de-
scribed previously [22]. See Additional file 2 for details
of primer sequences. To generate cDNA, a single MaSC
was sorted into thin-walled 0.2 ml 96-well plates (Corning
Life Sciences, Amsterdam, The Netherlands) containing
first-strand buffer (Superscript III buffer (Invitrogen), 0.5%
Nonidet P40 (Pierce, Thermo Fisher Scientific, Cramlington,
UK), 1 mM dNTP mixture (Invitrogen), 1 mM DTT
(Invitrogen), SuperRNaseIN (Ambion, Life Technologies,
Paisley, UK)), 3.4 nM MO4d(T) primer and A. thaliana
spike mRNAs LTP4, LTP6 and TIM (Stratagene, Agilent,
Stockport, Cheshire, UK) added at serial tenfold pg/μl di-
lutions. Single cells sorted into first-strand buffer were
snap-frozen in liquid nitrogen and lysed at 65°C. Primer
was allowed to anneal at 45°C before addition of Super-
script III reverse transcriptase and incubation at 45°C.
The reaction was inactivated at 65°C for 10 minutes.
Unannealed primer was digested by exonuclease I (New
England Biolabs, Hitchin, UK) with 6.7 mM MgCl2 at
37°C. Removal of the RNA template and polyadenyla-
tion of the cDNA were carried out concurrently by the
addition of RNaseH (New England Biolabs), 1.5 mM
dATP (Invitrogen) and 30 units terminal deoxynucleoti-
dyl transferase (TdT, Promega, Southampton, UK) at
37°C. Four microlitres of polyadenylated cDNA was
used as template for PCR amplification in 1× ExTaq buf-
fer (TaKaRa Clontech, St Germain-en-Laye, France),
0.65 mM dNTP (Invitrogen), 8.25 μM MO4d(T) primer,
5 units ExTaq (TaKaRa) by incubating at 94°C for 1 minute,
50°C for 2 minutes, and 72°C for 2 minutes to allow
second-strand synthesis. Subsequently, 35 cycles of amplifi-
cation were performed by incubating at 94°C for 30 seconds,
60°C for 30 seconds, and 72°C for 2 minutes. The first
round of amplification was performed in triplicate, after
which the amplified cDNA was pooled. A second round of
amplification was performed in duplicate using 2 μl of the
pooled amplified cDNA as template in 1× ExTaq buffer
(TaKaRa), 0.2 mM dNTP (Invitrogen), 2 μM T7-MO4
primer and 5 units ExTaq (TaKaRa). Thirty-five cycles
of amplification were performed by incubating at 94°C
for 30 seconds, 60°C for 30 seconds, and 72°C for 2 mi-
nutes. The amplified cDNA was again pooled before
use.
In preliminary tests, monitoring of the amplification of
the spiked control RNA (LTP4 added at 10−2 pg, LTP6 at
10−3 pg and TIM at 10−4 pg; these values correspond to8,400, 900 and 90 molecules of RNA respectively) in sin-
gle cell samples from the CommaDβgeo [23] mammary
epithelial cell line demonstrated that using the proced-
ure amplification was linear and preserved relative
abundance of transcripts, although a small amount of
variation was inherent to the second round of amplifica-
tion (Additional file 3A). Furthermore, when qrtPCR for
seven genes (Gapdh, Ubc, Jag1, Jag2, Wnt4, Wnt5a and
Wnt10a; selected on the basis of probe availability) was
carried out on amplification material from 16 single
CommaD cells, 16 groups of 10 CommaD cells and on
unamplified cDNA collected from the bulk population,
the mean of the expression levels of the single cells was
not significantly different from the mean of expression
in the 16 groups of 10 cells or to expression levels in the
unamplified bulk cDNA. This analysis confirmed that
relative expression levels were preserved upon amplifica-
tion from a single cell with a strong correlation in rela-
tive expression levels obtained when comparing single
cell and 10-cell amplified material (R = 0.98) and single
cell amplified and whole population unamplified mater-
ial (R = 0.95) (Additional file 3B; R values calculated in
Excel).
Breast cancer data set collection
Three TNBC cohorts were used in this study. A total
of 579 cases described by Karn and colleagues
(Karn579) was downloaded from the Gene Expression
Omnibus, accession ID GSE31519 [24]. The second
TNBC dataset, referred to as Guy’s107, comprised the
TNBC extracted from the recent GSE40267 study [25].
The third TNBC dataset (Lehmann) is a compilation of
TNBC extracted from 24 gene expression profiling
data sets (including 228 cases of the Karn579 cohort)
all performed on the Affymetrix hg-u133a platform
(ETABM158, MDA133, GSE1456, GSE5327, GSE5847,
GSE7390, GSE1561, GSE11121, GSE2034, GSE2603,
GSE20194, GSE2990, GSE3494, GSE2109, GSE12276,
GSE18864, GSE7904, GSE16446, GSE19615, GSE31519,
GSE10780, GSE13787, GSE6596 and GSE5460) [26] on
which we carried out RMA pre-processing followed by
a combat normalisation to reduce batch effect [27]. For
ER+ tumours, we retrieved the NKI295 [28], TRANS-
BIG [29] and the GSE2990 [30] data sets and extracted
those cases which were termed positive for ER by
immunohistochemistry, resulting in 226, 134, 149
samples for NKI295, TRANSBIG and GSE2990, re-
spectively. Clinico-pathological features for each of
these data sets have been previously published in the
original manuscripts referenced above, except for the
Lehmann set, which is provided here as Additional file 4.
Details of ethical approval for patient material can be
found within the original publications relating to each
data set.
Table 1 Results of staining of cells sorted on slides for





MaSCs K14 (106) 0 19 81
K18 (106) 98 2 0
ERα (62) 100 0
MYOs K14 (79) 16 48 35
K18 (79) 100 0 0
ERα (60) 100 0
Luminal ER- K14 (128) 100 0 0
K18 (128) 2 52 46
ERα (65) 96 4
Luminal ER+ K14 (118) 100 0 0
K18 (118 0 20 80
ERα (60) 0 100
Cells were either double-stained for K14/K18 or single-stained for ERα and then
counterstained with DAPI. Examples of negative (−), weak (−/+) and positive (+)
staining and of double-stained MaSCs are shown in Additional file 5. ERα staining
was only scored as negative or positive. ERα, estrogen receptor alpha; MaSC,
mammary stem cell; MYO, myoepithelial cell.
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transcriptional profiles
The mouse MaSc gene signature derived from the SAM
was converted to a human gene list using Biomart ID
conversion (Ensembl Genes 72// mus musculus genes
GRCm38.p1). To establish the overall activity of the
MaSc genes signature in human breast cancers, we
applied our previously published Denoising Algorithm
based on Relevance network Topology (DART) [31],
which identifies genes within a signature with highly
correlated expression levels and uses these to infer mo-
lecular pathway activity. We also tested median centring
the gene expression of the data set and establishing the
activation of the whole MaSC gene signature by averaging
the relative expression values for all genes for each tumour.
The ‘DART’ activation score or averaged gene expression
for each sample in each cohort were determined and log-
rank tests were performed dichotomising the samples using
either top tertile or median cutoffs, depending on the data
set. Kaplan-Meier plots were generated for each data set to
provide a visualisation of survival stratification.
Breast cancer subtype classification
Centroid classification for the PAM50 molecular breast
cancer subtypes were performed as described previously
[25]. PAM50 and IntClust classifications were retrieved
from the original publications [5,32]. TNBC subtypes de-
scribe by Lehmann and colleagues were established
using the online TNBC-type program [33]. To determine
the four TNBC subtypes described by Burstein and col-
leagues [34], centroids for each subtype were extracted
and correlation analysis performed.
Statistics
All statistical tests were two-sided unless otherwise
noted. Hypergeometric testing was used to establish the
significance of overlap between two gene lists. All ana-
lyses were performed within the statistical R environ-
ment [35] unless otherwise noted.
Results
Isolation of high-purity basal mammary stem cells
To isolate MaSCs with high purity, a flow cytometry ap-
proach using the markers CD24, CD49f, c-Kit, Sca-1 and
CD45 was used [13] (Figure 1 and Additional file 1B,C).
Total epithelial cells were identified by expression of
CD24 and Sca-1 as previously described [13] (Figure 1A).
Luminal ER- progenitors (Gate I) and luminal ER+ cells
(Gate II) were further identified on the basis of previ-
ously defined staining patterns (CD24+/HighSca-1−c-Kit+
and CD24+/HighSca-1+c-Kit−, respectively) [13]. The basal
epithelial population was partitioned into MYOs (Gate III;
CD24+/LowSca-1−CD49Lowc-Kit−) and MaSC (Gate IV;
CD24+/LowSca-1−CD49Highc-Kit−) populations (Figure 1B)[13]. As previously [36], a high threshold for a cell being
‘CD49fHigh’ was set (5% most strongly stained CD49f-
positive cells in the basal population) in order to achieve a
very high purity of MaSCs (which amounted to 1.4 ± 0.5%
of the total mammary epithelium; mean ± standard devi-
ation (SD), n = 3 sorts).
To confirm that the gating strategy isolated MaSCs,
MYOs, luminal ER- cells and luminal ER+ cells, the
populations were sorted and characterised by qrtPCR
gene expression analysis, staining of cytospins and
in vivo functional (transplant) assays. qrtPCR analysis of
expression of a panel of previously defined cell type-
specific genes [16] demonstrated that the populations
isolated by the sorting strategy had the expected pattern
of gene expression. CD24+/LowSca-1−CD49Highc-Kit−
and CD24+/LowSca-1−CD49Lowc-Kit− cells expressed
high levels of Fzd1 and Keratin14 (Krt14; the gene en-
coding K14) (basal genes). Both CD24+/HighSca-1−c-Kit+
and CD24+/HighSca-1+c-Kit− cells expressed the pan-
luminal gene Keratin18 (Krt18; the gene encoding K18),
while CD24+/HighSca-1−c-Kit+ cells expressed the lu-
minal ER- gene Sox6 and CD24+/HighSca-1+c-Kit− cells
expressed the luminal ER+ genes Dmbt1 and Estrogen
receptor 1 (Esr1; the gene encoding ERα) (Figure 1C).
Staining of cells from the populations sorted on to
slides for K14, K18 or ERα showed that the popula-
tions which were positive for these antigens were
also those which had shown the highest levels of
Krt14, Krt18 or Esr1 gene expression respectively by
qrtPCR analysis (Table 1). One hundred percent of
CD24+/LowSca-1−CD49Highc-Kit− MaSCs and 84% of
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these cells were also K18 negative, although two rare
double-positive MaSCs were observed (Additional
file 5). In contrast, all luminal cells were K18 positive and
K14 negative, with strongest K18 staining seen in the
CD24+/HighSca-1+c-Kit− luminal ER+ population. Im-
munofluorescence staining for ERα confirmed that the
CD24+/HighSca-1+c-Kit− cells were 100% ERα positive.
There was a small number (4%) of ERα-positive cells in
the CD24+/HighSca-1−c-Kit+ luminal ‘ER-’ population, also
in agreement with previous data [14].
To finally validate the sorting strategy using the
cleared mammary fat pad transplant assay, the MaSC,
MYO, luminal ER+ and luminal ER- populations were
sorted and transplanted into cleared fat pads at 200 cells
per fat pad over three independent cell sorts and trans-
plantations. After 8 weeks, glands were harvested,
whole-mounted, carmine stained to enable visualisation
of outgrowths and scored. The results (Figure 1D)
showed that only the CD24+/LowSca-1−CD49Highc-Kit−
MaSC population had the ability to repopulate a mam-
mary fat pad with high efficiency and, when taken in
conjunction with the qrtPCR and cell-staining data, con-
firmed that the sorting strategy was able to isolate
MaSCs, MYO, luminal ER- and luminal ER+ cells.
MaSCs have a distinct gene expression profile to
myoepithelial and luminal cells
MaSCs are localised in the basal cell layer of the mam-
mary epithelium. While MaSCs exclusively show re-
population capacity, they share a number of features
with the other, most numerous, cell type of the basal cell
layer, the MYOs. For instance, both MaSCs and MYOs
express K14, although Krt14 gene expression is slightly
higher in MaSCs than MYOs [37]. Direct comparison
between luminal cell gene expression and MaSC gene
expression, even when using highly purified populations,
will identify genes associated with the basal cell layer as
a whole, as well as the MaSC genes. Therefore, the com-
parison between the highly purified MaSC and myoe-
pithelial populations is essential in identifying genes
solely characterising the MaSC population.
We had previously profiled purified luminal ER+ and
luminal ER- cells and the total basal epithelial popula-
tion, which is dominated by MYOs [16]. To extract
MaSC-specific but not common ‘basal’ genes or a MYO-
dominated gene set, gene expression using Affymetrix
microarray of highly purified CD24+/LowSca-1−CD49Highc-
Kit− MaSCs and CD24+/LowSca-1−CD49Lowc-Kit− MYOs
was carried out. These data were integrated with our pre-
vious work on the total basal and two separated luminal
ER- and luminal ER+ cells populations [16] analysed on
the same Affymetrix gene expression platform. Analysis of
the distribution of the raw data from both the previousarrays and our new analyses showed no batch effects be-
tween the data sets that might have skewed results
(Additional file 6A). Unsupervised hierarchical cluster-
ing of gene expression data (Figure 2A) demonstrated
that the individual samples of the total basal cells
(CD24-/LowSca-1−) from our previous analysis [16] and
the new MYO (CD24+/LowSca-1−CD49Lowc-Kit−) and
MaSC (CD24+/LowSca-1−CD49Highc-Kit−) samples were
more similar to each other than to the two luminal pop-
ulations. Notably, however, individual samples from the
total basal, MYO and MaSC populations clustered with
each other. In particular, the seven MaSC samples
formed a distinct branch within the basal cluster. This
suggested that the transcriptome of the MaSC samples
was distinct to those of both the luminal, total basal and
MYO populations. By applying a series of two-class un-
paired SAM comparisons [15], genes significantly up-
regulated in the MaSCs relative to all other populations
were determined as follows. First, MaSC genes signifi-
cantly upregulated in the MaSCs compared to the
MYOs were identified, using a FDR of <5% and a fold
change cutoff of 1.5. Such an approach will inevitably
identify some genes that are expressed in MaSCs at a
higher level than in myoepithelial cells but are in fact,
when all cell populations are considered, much more
highly expressed in luminal populations. This is partly
due to the relative, rather than absolute, quantitative na-
ture of the approach but also likely to result from
‘lineage priming’ [38]. Therefore, the MaSC gene ex-
pression data were also separately compared to the lu-
minal ER- (CD24HighSca-1−) and ER+ (CD24HighSca-1+)
populations. Applying an FDR <5% and a cutoff of 1.5
fold change, 323 genes were identified as significantly
upregulated in MaSCs relative to all the other popula-
tions and considered to be MaSC-specific (Additional
file 7). Of these 323 genes, 69 were expressed >2.5 fold
higher in the MaSCs relative to both the MYO and
combined luminal populations (Table 2; Figure 2B).
Fourteen genes (Cdh5, Gfra2, Krt15, Lgals1, Lgr5,
Nfatc1, Pdgfb, Prox1, Ptprb, Ptprz1, Tnc, Vim, Zeb1,
Zeb2) were selected to validate the Affymetrix-obtained
MaSC gene expression by qrtPCR analysis of independ-
ent RNA samples isolated in three mammary cell prepa-
rations and sorts. These genes were selected on the basis
of their identification by other authors as of potential
interest in embryonic development and/or adult normal
and cancer stem cell biology [10,11,39-46]. Importantly,
the RNA used for this validation was unamplified. Valid-
ation was carried out on the luminal ER- (CD24+/High-
Sca-1−c-Kit+), luminal ER+ (CD24+/HighSca-1+c-Kit−),
MYO (CD24+/LowSca-1−CD49Lowc-Kit−) and MaSC
(CD24+/LowSca-1−CD49Highc-Kit−) subpopulations. In
agreement with the microarray data, 13 of 14 genes
were significantly more highly expressed in the MaSCs,
Figure 2 (See legend on next page.)
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Figure 2 MaSCs have a distinct gene expression profile. (A) Unsupervised hierarchical clustering heatmap of genes differentially expressed
between MaSC, MYO, total basal, luminal ER- (ER-) and luminal ER+ (ER+) mammary epithelial subpopulations. Expression values represent
median-centred value for each probeset. (B) Unsupervised hierarchical clustering of microarray expression data of the 69 top MaSC signature
genes (Table 2) across the MaSC, MYO, total basal, ER- and ER+ populations. (C) qrtPCR validation of MaSC genes of interest identified by whole
transcriptome microarray analysis. Expression of Cdh5, Gfra2, Krt15, Lgals1, Lgr5, Nfatc1, Pdgfb Prox1, Ptprb, Ptprz1, Tnc, Vim, Zeb1, Zeb2 in luminal
ER-, luminal ER+, MYO and MaSC unamplified RNA determined by qrtPCR analysis. Data expressed as mean relative fold expression (±95%
confidence intervals) over comparator population (luminal ER- cells) in three independent isolates of each cell population. Statistical significance
was determined according to [74]. **P <0.01; *P <0.05; N.S not significant, relative to the next highest expressing population indicated by brackets.
ER, estrogen receptor; MaSC, mammary stem cell; MYO, myoepithelial cell; qrtPCR, quantitative real-time rtPCR.
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exception was Prox1, which was more highly expressed in
MaSCs than MYOs but was expressed at similar levels in
MaSCs and both luminal populations (Figure 2C).
To interrogate the 323 MaSC genes for functional as-
sociations, analysis of the total MaSC gene list was car-
ried out using the DAVID Gene Ontology (GO) tool and
the ROCK database pathway analysis tool [17,19,20]
(Figure 3A and Additional file 8). The MaSC gene signa-
ture was most highly enriched for genes associated with
transcription, intracellular signalling, cell adhesion and
cytoskeletal organisation/cell migration/axonal guidance
(Figure 3A). Pathway analysis highlighted a number of
pathways associated with genes in the signature includ-
ing, notably, smooth muscle contraction, interactions
with the extracellular matrix/integrins and Wnt signal-
ling (Additional file 8).
The top 100 genes most strongly downregulated in the
MaSCs compared to the MYOs are shown in Additional
file 9, with GO analysis of these genes in Additional file
10. Since many of these genes are not well-annotated, no
significant enrichment for a particular pathway was
identified. GO analysis also offered only limited insights,
although there was enrichment for genes associated with
transcription, immune system regulation, apoptosis and
haematopoietic development.
A notable absence from the list of MaSC-specific
genes was Procr, recently suggested as a marker of multi-
potent MaSCs with epithelial-mesenchymal transition
(EMT)-like features [47]. To directly test Procr expres-
sion in our mammary cell subpopulations, qrtPCR gene
expression analysis was carried out on MaSCs, MYOs,
luminal ER- and luminal ER+ subpopulations as defined
in Figure 1. There was no significant difference in Procr
expression between MaSCs and MYOs and, indeed, Procr
expression could be detected in luminal ER+ cells (al-
though at lower levels than in MaSCs; Additional file 6B).
Comparison of the MaSC signature to previously identified
stem cell signatures
Previous studies have identified human and mouse ‘MaSC
signatures’ using either freshly isolated cells [10,12] or
mammosphere cultures [11], with the caveats noted
above. To establish whether any genes were identifiedcommon to these studies, gene expression signatures from
these studies were overlaid with the signature reported
here (Figure 3B-E and Additional file 11). Only one gene
was common between our MaSC signature and the genes
identified by Stingl and colleagues [12], namely fatty acid-
binding protein 4, adipocyte (Fabp4). This gene has
recently been shown to mark a population of adipocyte
progenitors but has not yet been linked functionally to
MaSCs [48]. Fifty genes were found in common between
our MaSC gene signature and the signature identified by
Lim and colleagues [10]. Of the genes expressed in stem
cells isolated from mammosphere cultures using a label-
retaining strategy [11], 17 were shared with the MaSC
signature reported here (Figure 3B).
To assess whether adult MaSCs share gene expression
profiles with their more primitive embryonic counter-
parts, the MaSC signature was compared to two embry-
onic mammary bud studies. One study profiled the gene
expression signatures of the constituent tissues of puri-
fied mammary primordia, the mammary bud epithelium
(MBE) and mammary bud mesenchyme (MBM) [40].
The other compared CD24HighCD49fHigh fetal MaSC
(fMaSC) against either CD24Med/Low/Neg fetal stromal
cells or adult CD24LowCD49fHigh MaSCs [39].
Only three genes overlapped between our MaSC signa-
ture and both embryonic epithelial profiles, namely
Nkain2, Mtap7 and Mbp (Figure 3C; Additional file 11,
highlighted in red). However, 27 genes from the MaSC
signature were expressed in one of the two profiles.
Furthermore, there were 11 adult MaSC genes that
overlapped with both previously identified embryonic
mesenchymal/stromal profiles, namely Dab2, Ebf3,
Flt1, Klf12, Ldb2, Ogn, Samd4, Tek, Tfpi, Wscd2 and
the Riken ORF 9030425E11Rik (Figure 3D; Additional
file 11, highlighted in blue). There were 54 genes in
common between our MaSC gene signature and the
adult MaSC profile identified by Spike and colleagues
(Figure 3E; Additional file 11). Taken together, 109 out
of 323 genes (34%) in the MaSC signature have already
been associated with adult mammary stem cell features in
at least one other study. GO Bioprocess analysis annotates
28 of these 109 genes (Aebp1, Akap2, Cd36, Cdh5, Cdh13,
Cldn5, Cntn2, Col12a1, Col18a1, Col 6a2, Dclk1, Dst,
Emcn, Flt1, Gsn, Lgals1, Mtap1b, Myh11, Nexn, Ngfr,
Table 2 Expression of top 69 MaSC signature genes
expressed >2.5 fold higher and <5% FDR relative to
expression in both myoepithelial and luminal cells,





Gene symbol Fold change FDR (%) Fold change FDR (%)
4933439F18Rik 2.60 2.44 4.93 0
Adam12 5.40 2.45 2.77 0
Bcor 2.77 3.37 2.87 0
Bptf 3.98 3.49 7.57 0
Ccnd2 2.83 3.49 8.89 0
Cdk5rap2 2.64 0.58 3.33 0
Cdkl2 2.66 1.75 2.86 0
Col12a1 3.76 2.85 4.18 0
Col17a1 6.72 3.49 2.51 0
Col5a2 2.97 0.58 3.55 0
Dab2 3.53 3.49 2.51 0
Depdc6 2.63 2.25 3.88 0
Diap2 2.54 2.85 2.97 0
Dlc1 2.54 3.37 5.57 0
Dpysl3 2.68 3.49 4.92 0
Eif2ak2 2.75 2.85 2.83 0
Elk3 2.68 3.49 3.26 0
Erg 2.64 2.85 2.55 0
Fabp4 3.59 2.44 2.50 0
Filip1 2.55 4.30 2.68 0
Gfra2 3.21 0.37 10.55 0
Gltscr2 2.51 3.49 2.71 0
Gpatch4 2.63 3.90 3.28 0
Grik3 3.29 0.96 4.53 0
Gsn 2.73 2.44 2.98 0
Htr1d 2.78 2.02 5.85 0
Ift57 2.90 0.00 3.18 0
Kank2 3.19 1.59 4.23 0
Kif26b 4.02 0.00 3.64 0
Krt15 3.38 1.75 3.15 0
Lgals1 3.01 0.00 6.39 0
Lgr5 7.76 0.00 2.94 0
Ltbp2 2.87 0.00 6.94 0
Mllt3 2.88 2.06 5.10 0
Mme 3.17 1.59 4.29 0
Mtap1b 6.74 2.08 3.64 0
Mybl1 3.05 2.06 3.17 0
Nf2 3.14 3.37 3.46 0
Nfatc2 2.81 1.54 6.35 0
Ngfr 2.95 3.49 3.16 0
Table 2 Expression of top 69 MaSC signature genes
expressed >2.5 fold higher and <5% FDR relative to
expression in both myoepithelial and luminal cells,
ordered by gene symbol (Continued)
Nkain2 3.14 2.23 3.78 0
Nox4 5.04 0.58 2.69 0
Ogn 5.79 1.71 2.68 0
Pcdh7 2.68 3.49 5.51 0
Pdcd6ip 2.93 2.85 3.77 0
Plcb1 2.87 1.10 2.72 0
Ppp1r14a 2.61 3.49 3.14 0
Rarres2 2.90 2.06 2.87 0
Rpf2 3.95 4.30 3.36 3.98
Runx2 2.60 2.44 2.95 0
Samd4 4.94 1.75 5.49 0
Scaper 3.69 3.49 2.68 1.86
Scube3 3.71 0.58 4.39 0
Sfrp1 3.51 1.55 5.20 0
Sgcb 2.61 1.99 2.79 0
Sh3d19 2.94 2.44 5.46 0
Slc35f1 5.18 2.06 2.61 0
Slco2a1 3.38 2.08 4.18 0
Slu7 2.80 3.56 2.54 0
Stk39 3.20 3.49 4.15 0
Sync 2.58 2.44 3.86 0
Synpo2 3.56 1.59 4.10 0
Thsd7a 3.41 3.90 2.50 0
Tm6sf1 3.83 2.44 2.65 0
Tnc 21.41 0.00 2.65 0
Trak1 2.96 4.30 4.86 0
Vsnl1 5.30 0.00 5.35 0
Wipf1 2.75 0.58 3.98 0
Zfhx3 3.32 2.06 3.82 0
MaSC, mammary stem cell; FDR, false discovery rate.
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involved in adhesion, migration and/or cytoskeletal reor-
ganisation, supporting a role in invasion/metastasis.
Fifteen of the 109 genes (Cdh13, Col17a1, Cpne8, Dst,
Epas1, Fabp4, Jam2, Krt15, Lmod1, Mical3, Myh11, Ngfr,
Ntn4, Ppp1r14a, Tns1) have been identified in two or
more studies in addition to our own, providing further
support for their involvement in the biology of this cell
type.
Single cell resolution analysis of MaSCs demonstrates
co-expression of epithelial and mesenchymal features
GO analysis had demonstrated that the MaSC gene
signature included classes of genes associated with cell
Figure 3 (See legend on next page.)
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Figure 3 Analysis of the MaSC gene signature. (A) Breakdown of GO Bioprocess classifications of MaSC gene signature based on DAVID
annotation clustering (Additional file 5). (B-E) VENNY analysis of overlap between MaSC signature and published data sets [10-12,39,40]
(Additional file 6). (B) Overlap with published Stingl, Lim and Pece gene lists of adult stem cell genes. (C) Overlap with Wansbury fetal mammary
bud epithelium and Spike fetal mammary stem cell genes. (D) Overlap with Wansbury fetal mammary mesenschyme and Spike fetal mammary
stroma genes. (E) Overlap with Spike fetal and adult stem cell gene lists. GO, Gene Ontology; MaSC, mammary stem cell.
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expression analysis may mask important transcriptional
or functional heterogeneity within populations being
assayed. Therefore, to test the heterogeneity of MaSCs
and whether they had the potential to be further divided
into functional subtypes, we analysed expression of a
subset of MaSC-signature genes in individual MaSCs
using a single cell resolution gene expression protocol
[22]. The protocol is based on two rounds of PCR ampli-
fication of reverse-transcribed RNA. Importantly, it
includes spiking input RNA with exogenous RNA of
known amounts (from Arabidopsis thaliana), both to act
as internal controls for ΔΔCt calculations and to moni-
tor linearity of amplification during the procedure. See
Methods for details of validation steps used for the
protocol.
We analysed 32 individual MaSCs by qrtPCR for
expression of a panel of 12 genes identified by the Affy-
metrix microarray analysis as significantly more highly
expressed in MaSCs than in the other mammary epithe-
lial populations (Figure 4). Expression of some genes
was highly variable across the individual single cells (for
example Krt15 and Vim) while for others, expression
was more consistent (for example Pdgfb, Ptprb and
Ptprz1) (Figure 4A). Although Krt15 and Vim expression
defined distinct sets of cells (double positives, single pos-
itives and double negatives) (Figure 4B), each pattern of
expression of the 12 genes tested was typically unique to
each cell, although some patterns were found in two of
the cells tested (numbering the cell profiles in Figure 4B
from left to right, cells 23 and 24 appear almost identi-
cal, as are 30 and 31). Classes of cells with overall gene
expression patterns that were similar within classes but
very different between the classes were not observed and
were not defined by unsupervised hierarchical clustering
(Figure 4B). This was further supported by the lack of sig-
nificance in Pearson correlations between gene (Figure 5
and Additional file 12) and suggests that MaSCs cannot
be divided into cell subsets with uniform patterns of gene
expression. Rather, individual cells sampled at any
particular point in time (co-)express genes associated
with a particular phenotype - epithelial-associated or
mesenchymal-associated genes for example - in unique
patterns and without necessarily expressing the full tran-
scriptional programme of that phenotype.
Epithelial and mesenchymal features of stem cells are
of particular interest because EMT has been reported asa characteristic of cancer stem cells and mesenchymal-like
features are associated with increased migration and inva-
sive potential [9,49,50]. However, it should be noted that
co-expression of epithelial-associated and mesenchymal-
associated genes/proteins in the mammary epithelium is
not unique to the mammary stem cells. Indeed, the
basal cell population in the mammary epithelium, which
is >90% MYOs [13], is known to express both mesenchy-
mal and epithelial markers, whether shown by immuno-
fluorescence for example K14, α-SMA and Vim [14,51,52]
or gene expression profiling of bulk populations for ex-
ample Krt5, Krt14, Mylk, Snai2, Vim [16]. We confirmed
this here by immunohistochemical staining of serial sec-
tions of normal mouse mammary gland for K14, SMA
and Vim expression. The basal cell layer of the mammary
epithelium shows strong expression of K14 and SMA in
all cells, and weaker, punctate Vim staining in a subset of
cells (Additional file 13A). It is clear that both MaSCs and
MYOs co-express epithelial and mesenchymal markers;
nevertheless, patterns of co-expression of epithelial- and
mesenchymal-associated genes in stem cells in particular
are of interest in informing our understanding of the
biology of EMT-MET conversions in cancer stem cells.
Therefore, the co-expression of Krt15 (K15), an epithelial-
associated gene, and Vim (Vim), a mesenchymal-associated
gene, and their respective proteins were examined in the
single MaSCs in more detail.
1/Ct qPCR expression levels of Krt15 and Vim for
each individual cell showed that the majority of cells co-
expressed both genes; of the 32 cells analysed, 2 (6.2%)
were double negative, 7 (21.9%) expressed Krt15 but not
Vim, 3 (9.4%) expressed Vim but not Krt15 and 20
(62.5%) were double positive (Figure 5B). Therefore,
more than half of MaSCs do express both genes. Fur-
thermore, when MaSCs were flow sorted on to slides
and double stained with antibodies against K15 and Vim
(n = 234 cells stained and counted from three separate
cell preparations), most cells (92.5 ± 2.5%) were positive
for both K15 and Vim. A few cells were positive for only
one marker (K15 1.3 ± 1.0%, Vim 4.0 ± 1.0%) or double
negative for both proteins (2.2 ± 1.7%). Thus the popula-
tion variation in expression of Krt15/K15 and Vim/Vim
seen at mRNA level is less evident at the protein level
(Figure 5C). Most MaSCs therefore simultaneously ex-
press at least some aspects of the epithelial and mesen-
chymal biological programmes but do not necessarily
show either a full epithelial or mesenchymal phenotype.
Figure 4 Individual MaSCs have diverse gene expression patterns. (A) Coefficients of variation of gene expression between individual
cells are variable, with some being highly diverse (Krt15, Vim) and others more uniform (Pdgfb, Ptprb, Ptprz1). Data presented as 1/Ct values.
(B) Unsupervised hierarchical clustering of median-centred qrtPCR gene expression data on 12 genes from 32 individual MaSCs. Note there are
no obvious blocks of similarity of gene expression across the whole panel between the cells. MaSC, mammary stem cell; qrtPCR, quantitative
real-time rtPCR.
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metastasis-free survival in breast cancer
Having established a robust MaSC gene set, we asked
whether these genes were expressed in human primary
breast cancers and if their expression provided any evi-
dence that the biology of MaSCs as reflected in their
gene signature has relevance for breast cancer progres-
sion. We initially examined TNBCs as these tumours
strongly overlap with the basal-like intrinsic molecular
subtype of breast carcinomas, which have previously
been associated with a high proportion of stem cell-like
cells, both in terms of flow cytometric phenotype and
functional assays [9,53,54]. Mouse genes of the MaSC
signature were converted to Ensembl human gene iden-
tifiers and the activation of the MaSC gene signature in
two independent TNBC cohorts was determined. One
previously published dataset, the Karn579 dataset, is a
compilation of 579 TNBC extracted from several breastcancer cohorts [24]. The second comprises the Guy’s107
TNBC, which includes the TNBC samples from the
Guy’s collection [25]. In addition, we compiled a third
cohort of TNBC, extracted across 24 different breast
cancer cohorts of the Lehmann dataset [26] including
228 tumours of the Karn579 dataset. Applying our previ-
ously established DART algorithm [31], for each patient
in each cohort a DART score was calculated based on
expression of the MaSC gene signature, whereby a high
activation score indicated a high similarity of gene ex-
pression with the MaSC signature. Heatmap analysis of
expression of the 323 genes in the Karn579 dataset or-
dered from low to high MaSC DART signature tumours
(Additional file 13B) confirmed that those tumour pro-
files with the highest signature scores visibly showed
higher average expression of the 323 genes and vice
versa. By splitting the Karn579 cohort into those patients
with the top tertile DART activation score compared to
Figure 5 The MaSC population does not contain distinct subpopulations. (A) Pearson correlation between gene expression profiles of
individual cells showing a low level of correlation in gene expression between cells (see Additional file 12 for details). (B) Comparison of Vim
and Krt15 gene expression in individual MaSCs by qrtPCR. Data presented as 1/Ct values. (C) Examples of K15 single-stained and K15/Vim
double-stained MaSCs. Bar = 10 um. K15, keratin 15; MaSC, mammary stem cell; qrtPCR, quantitative real-time rtPCR; Vim, vimentin.
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of high MaSC for recurrence-free survival (RFS) was
highly significant in TNBC when analysed as a categor-
ical variable (hazard ratio (HR) = 2.165; confidence inter-
val (CI) (1.599 to 2.931); P = 5.78e to 07). Many TNBCs
with high MaSC expression relapsed in the first 5 years.
In the Guy’s107 TNBC cohort we saw the same result
for TNBCs with DART scores above the median when
considering distant metastasis-free survival (DMFS)(HR = 3.029; CI (1.393 to 6.586); P = 0.00517) (Figure 6B)
and the extended Lehmann dataset, although not inde-
pendent of the Karn579 dataset (as noted in the Methods),
confirmed this result (HR = 1.52; CI (1.021 to 2.263);
P = 0.0391) (Figure 6C). Use of the two overlapping
data sets (228 tumours in common), demonstrated
that the prognostic power of our MaSC gene signature
is independent of data set composition and analytical
preprocessing of the expression data. Furthermore, analysis
Figure 6 (See legend on next page.)
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Figure 6 The MaSC gene signature predicts a significantly shorter DMFS in TNBC. Kaplan-Meier survival curves showing distant metastasis-free
survival (DMFS) in three cohorts of TNBC and three of ER+ breast cancer. Stratification is based on top tertile of samples with high DART activation
score for enrichment of MaSC gene signature compared to the rest, with the exception of the Guy’s107 TNBC dataset, which was stratified
using the median activation score as a cutoff. (A) Karn579 TNBC [24]. (B) Guy’s107 TNBC [25]. (C) Lehmannn TNBC [26]. (D) NKI295 ER+ [28].
(E) GSE2990 ER+ [30]. (F) TRANSBIG ER+ [29]. DART, Denoising Algorithm based on Relevance network Topology; ER, estrogen receptor; MaSC,
mammary stem cells; TNBC, triple-negative breast cancer.
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signature, and with a similar expression distribution, taken
from the Karn579 data illustrated that we would have not
observed such a significant P value by chance (indicated
with a red line in Additional file 14A). Since none of the
clinico-pathological features in the 579Karn data showed
a significant association with RFS, a multivariate survival
analysis was not performed (Additional file 15).
To test the prognostic power of the MaSC gene signa-
ture using an orthogonal approach, breast cancer
transcriptional profiles were also analysed by deriving a
MaSC signature score from the centred, averaged rela-
tive expression levels of the MaSC genes for each
tumour and including this score in the survival analysis.
In agreement with the DART method, the standardised
average of the 323 genes was higher in tumours with an
overall shorter RFS (Additional file 14B), confirming the
relevance of the MaSC biological programme invasion
and metastasis in TNBC.
To determine whether the prognostic power of the
signature could be extended to ER+ breast cancer, we in-
vestigated the activity of the MaSC gene signature in ER+
tumours of three different breast cancer cohorts, namely
the NKI295 dataset (226 ER+ tumours/295 samples) [28],
the TRANSBIG dataset (134 ER+ tumours/198 samples)
[29] and the GSE2990 dataset (149 ER+ tumours/189
samples) [30]. Strikingly, in the ER+ tumours of the
NKI295 and the GSE2990 data sets, we observed the op-
posite effect to that seen in TNBC. ER+ tumours with
high MaSC DART activation scores had better DMFS in
comparison to the rest (HR = 0.545, CI (0.3374 to 0.8816),
P = 0.01335 for NKI295; HR = 0.303, CI (0.116 to 0.7913),
P = 0.01478 for GSE2990) (Figure 6D,E). However, in the
TRANSBIG cohort, no association of the MaSC DARTac-
tivation score could be observed in the ER+ breast cancers
(Figure 6F).
Breast cancer subtype-specific expression of the MaSC
signature
Next, we asked whether our MaSC gene signature was
associated with a specific subtype across all breast cancers
and within TNBCs. We made use of the comprehensive
METABRIC breast cancer data set and interrogated which
of the PAM50 and IntClust subtypes were enriched for tu-
mours with a high MaSC signature DARTactivation score.
Interestingly, tumours with a high MaSC signature wereenriched in the normal-like subtype (Figure 7A), followed
by the claudin-low and luminal A subgroup. With the
IntClust classification, an enrichment of MaSC signature
high tumours was observed in IntClust3 and IntClust4
(Figure 7B). These clusters encompass relatively genomi-
cally stable tumours and mainly include luminal A tu-
mours, although IntClust4 also includes subsets of HER2
and basal-like tumours as well as the normal-like group,
supporting the PAM50 analysis. Tumours of the IntClust3
and 4 subtypes have been associated with relatively good
prognoses [5], in agreement with our results in the ER+
data sets (Figure 6D,E).
Finally, we investigated the activation of MaSC gene
signature across TNBC subgroups by subtyping the
Karn579 cohort with the four TNBC subtypes recently
established by Burstein and colleagues [34] namely
luminal-AR (LAR), mesenchymal (MES), basal-like im-
mune-suppressed (BLIS), and basal-like immune-activated
(BLIA); and the six TNBC subtypes identified by Lehmann
and colleagues [33], namely two basal-like (BL1 and BL2),
an immunomodulatory (IM), a mesenchymal (M), a mes-
enchymal stem-like (MSL), and a luminal androgen recep-
tor (LAR) subtype. The tumours with the highest MaSC
activation scores were found in the MES subtype in the
Burstein classification. In the Lehmann classification the
findings were less distinct, with enrichment in the MSL
subtype as well as in BL2 and M tumours (Figure 8A,B).
To test whether our MaSC can equally stratify these
TNBC subtypes with regards to outcome, we first investi-
gated the RFS for each of the five TNBC Lehmann sub-
types in the Karn579 cohort (Figure 8C), showing that the
MSL and IM had overall better prognosis than the other
subtypes. Then we dichotomised each TNBC subtype with
our MaSC signature DART score as described above. Sur-
vival analysis demonstrated that indeed the BL1, BL2 and
M TNBC subtypes could be further stratified by the MaSC
signature into those tumours that relapsed within the
first 3 years and those with a longer latency period
(Figure 8C-F). Taken together, our results demonstrate
that we have identified a set of genes that captures a
specific stem cell programme that holds biological and
clinical (prognostic) information in breast cancer.
Discussion
TNBC, as a whole, has a poor prognosis and unlike ER+
and HER2+ tumours currently lacks targeted therapies,
Figure 7 The MaSC gene signature is enriched in normal-like not claudin-low tumours. The DART activation score of the MaSC gene
signature across breast carcinomas of METABRIC breast cancer cohort. The classification of this cohort into molecularly defined breast cancer
subtypes was based on their previously published PAM50 centroid correlation (upper panel) (basal-like in red, HER2 in pink, luminal A in dark
blue, luminal B in light blue, and normal-like in green) and across the 10 previously defined IntClust subgroups (lower panel). Number of tumours
is shown underneath each subtype. The DART activation score of the MaSC gene signature is shown on the y-axis in both plots. DART, Denoising
Algorithm based on Relevance network Topology; HER2, human epidermal growth factor receptor 2; MaSC, mammary stem cell.
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treatment option. These immunohistochemically defined
breast carcinomas comprise a histologically, molecularly
and clinically highly heterogeneous group of tumours,
with some patients having low long-term recurrence
rates and responding well to chemotherapy [55]. Thus,
there exists a clinical need to stratify patients to ensure
the most appropriate treatment is administered. One
approach to identification of high-risk disease sub-
groups in breast cancer is prognostication based on
gene expression profiling of primary tumours [56].
Given large tumour cohorts, clinical outcome data and
whole transcriptome expression profiles of tumours, it
is possible to identify sets of genes whose expression
has prognostic value. In ER+ disease, these have typic-
ally been genes associated with proliferation [57].
Recent studies have shown that the expression of
immune-response genes [58], a metastasis regulator
metagene [59] or a chromosomal instability metagene[60] may represent potential prognostic markers for
TNBC.
Here, we have used our experience in separation of
mammary epithelial cell subsets to isolate a highly puri-
fied population of MaSCs and derive a gene signature
based on comparison to differentiated MYOs as well as
to luminal ER+ and luminal ER- cells. Remarkably, the a
priori-defined MaSC gene signature was able to provide
prognostic information when applied to gene expression
profiles of human breast cancers that had undergone no
purification protocols or microdissection of tumour
tissue. Therefore, the biology of normal MaSCs, as
reflected in their gene expression profiles, is highly rele-
vant for understanding the drivers of aggressive disease
in TNBC. The gene signature was able to identify TNBC
patients with a particularly poor prognosis (especially
within the recently identified BL1, BL2 and M subtypes)
and who thus might benefit from a more aggressive ther-
apy regime or potential enrolment on to clinical trials of
Figure 8 (See legend on next page.)
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Figure 8 The MaSC gene signature has prognostic power in specific TNBC subtypes. The DART activation score of the MaSC gene
signature across the Karn579 cohort is shown using (A) the Lehmann TNBC subtype classification [26]. TNBC subtypes are represented pink for
basal-like 1 (BL1), blue basal-like 2 (BL2), orange immunomodulatory (IM), grey mesenchymal (M), magenta mesenchymal stem-like (MSL), green
luminal androgen receptor (LAR), and (B) centroid classification of TNBC subtypes defined by Burstein and colleagues [34], namely the ‘luminal
androgen receptor (LAR)’, ‘mesenchymal (MES)’, ‘basal-like immune-suppressed (BLIS)’, and ‘basal-like immune activated (BLIA)’ groups. MaSC DART
scores are shown in the y-axis. (C) Kaplan-Meier analysis of the Karn cohort stratified according to the six TNBC subtypes defined by Lehmann
and colleagues [33]. Kaplan-Meier analysis of event-free survival with follow-up information is shown. (D) BL1, (E) BL2 and (F) M classified TNBCs
of the Karn579 data were analysed separately and stratified according to the highest tertile of their MaSC DART score activity. DART, Denoising
Algorithm based on Relevance network Topology; MaSC, mammary stem cells; TNBC, triple-negative breast cancer.
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sive evaluation and refinement of the genes encom-
passed in this list to maximise its power and general
applicability is required before it could be considered
usable as a clinical tool.
In contrast to the TNBC data, in two data sets ER+
tumours with a high MaSC activation score had a better
prognosis, rather than a worse one. The difference in be-
haviour of the MaSC gene signature in these tumour
types is striking, but the reason for it remains unclear.
When all breast cancers in the METABRIC cohort were
considered, the MaSC signature was enriched in good
prognosis molecular profile tumour subsets (normal-like
and Integrative Cluster 3 and 4 tumours), supporting the
DART activation score analysis of the ER+ tumour data
sets. Moreover, the classification with PAM50 and
IntClust demonstrated that MaSC signature is not divid-
ing tumours histologically classified as TNBC into those
which are molecularly classified as basal-like and those
which are non-basal and have a better prognosis. Not-
ably, the identification of breast cancer stem cells has
been based on work primarily from TNBC [53] with
little success in identifying ER+ tumour stem cells that
will generate a tumour upon xenotransplantation, cur-
rently considered the gold standard assay [9]. However,
ER+ disease can recur more than 15 years after appar-
ently successful initial treatment [61], which indicates
ER+ tumours do possess a cancer stem cell population
but one which is quiescent and indolent, in contrast to
the aggressive and highly transplantable cancer stem
cells that are found in TNBC. This provides one possible
explanation why the activity of the MaSC signature iden-
tified tumours with opposite RFS in different breast
cancer subtypes - cells with features in common with
normal stem cells may be the most aggressive in TNBC
but, in the short term, the most indolent in ER+ disease
(with the potential to become aggressive in the long
term). Further extensive analysis is warranted to dissect
the differences of intrinsic and environmental factors
that will ultimately influence the stem cell behaviour and
their association with disease recurrence.
Analysis of the functional role of individual genes
within the MaSC signature may shed light on theunderlying biology of metastatic disease in TNBC tu-
mours as well as identifying novel therapeutic targets.
Of the 15 genes expressed in the MaSC signature as well
as in two or more adult mammary stem cell gene signa-
tures from other studies, four (Cdh13, Col17a1, Dst and
Jam2) are associated with cell junctions and either cell-
cell or cell-matrix adhesion and five (Krt15, Mical3,
Myh11, Ppp1r14a and Tns1) are associated with the
cytoskeleton or its regulation. Furthermore, Col17a1 is a
hemidesmosome component and therefore linked to the
keratin cytoskeleton, Dst also has a role in cytoskeletal
organisation and Tns1 is associated with focal adhesions
[62]. The regulation of the cytoskeleton by adhesion to
other cells and to the matrix therefore seems to be a key
component to MaSC biology. Also of interest in the 15
recurrent genes is Epas1, which encodes hypoxia indu-
cible factor 2α. Notably, hypoxia in tumours is thought
to be an inducer of EMT and cancer stem cell-like activ-
ity [63]. Another recurrent theme in regulation of epi-
thelial stem cells is the role of Wnt signalling [64]. For
instance, Wnt pathway activation is required to maintain
stem cell self-renewal in cultured mammary epithelial
cells [65] and Wnt signalling was found to be suppressed
in MaSCs after pregnancy [66], consistent with our MaSC
gene signature (from virgin animals) being enriched for
Wnt pathway-associated genes.
The MaSC signature is of a population with mixed
mesenchymal/epithelial features (as supported by the
single cell analysis), which would not necessarily be ex-
pected to be most strongly enriched in tumours with a
pure EMT signature. The mixed nature of the signature
also likely explains the small overlap with the signature
of Lim and colleagues [10]. There was an overlap of only
a single gene with the stem cell signature reported by
Stingl and colleagues [12]. However, Stingl and colleagues
reported only four genes as upregulated >2 fold in stem
cells compared to both MYOs and luminal progenitors
(Ma-CFCs, to use their terminology), and the most highly
upregulated of these genes was expressed only 2.4 fold
higher in the stem cells compared to the other popula-
tions. Given these numbers, the single gene overlap
(Fabp4) is a statistically significant event (Additional
file 11). Indeed, Fabp4 is one of fifteen genes identified
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stem cell-specific.
Previous identification of mesenchymal gene expression
within the basal population as a whole, encompassing
both the myoepithelial and MaSC population, has been
largely explained by the contractile role of mature MYOs
[9,53,54]. Direct comparison between the MaSC and
myoepithelial populations showed that MaSCs express
higher levels of some mesenchymal- and epithelial-
associated genes such as Vim and Zeb2 (mesenchymal)
and Krt15 (epithelial). We have previously demonstrated
by qrtPCR that MaSCs also express Krt14 approximately
1.5 fold higher than MYOs [37], although the differential
is not sufficient to be classed as significantly upregulated
in MaSCs in the microarray analysis presented here. Single
cell gene expression analysis identified individual MaSCs
that either co-expressed Vim and Krt15, expressed Vim or
Krt15 alone or were negative for both. However, immuno-
fluorescent staining of flow-sorted MaSCs showed that,
at the protein level, the majority of MaSCs were positive
for both Vim and K15. These findings confirmed co-
expression of mesenchymal- and epithelial-associated
genes in individual MaSCs, although with a transcrip-
tional heterogeneity not necessarily reflected at the
protein level. We speculate that this is due to differ-
ences in mRNA and protein stability, although confirm-
ing this at single cell resolution will be technically
challenging. Although a feature of the normal biology of
basal mammary epithelial cells, the expression of mes-
enchymal genes in breast cancer (EMT) has been linked
both to aggressive, metastatic tumour progression and
the acquisition of stem cell traits in both malignant and
normal cells [9,49,50]. However, breast cancers with
abundant mesenchymal features (metaplastic spindle
cell carcinomas) are rare (approximately 1% of tumours)
and fewer than 7% of high-grade breast cancers contain
occasional mesenchymal-like cells [3,67,68]. As our
findings show, MaSCs express mesenchymal-associated
genes, and ‘EMT’ signatures in tumours may in fact re-
flect the expression of a stem cell-like biological
programme by tumour cells rather than a histologically
apparent EMT.
We have derived our stem cell signature from basal
stem cells defined operationally by their high transplant
potential in a cleared mammary fat pad [69]. However,
controversy exists as to whether the adult mammary epi-
thelium has a single basal stem cell population that
maintains both luminal and basal layers [70] or two dis-
tinct stem cell compartments, one basal and one luminal
[71]. Evidence for a separate luminal stem cell popula-
tion has been derived from lineage tracing experiments,
as luminal cells have poor transplantation potential [71],
although we have shown they can repopulate a cleared
fat pad [13]. A recent study has once again providedsupport for the existence of a common multipotent basal
mammary stem cell population defined by the expres-
sion of the protein C receptor (Procr+) [47]. However,
Procr expression was not enriched in our MaSC popula-
tion relative to MYOs in the microarrays. We have de-
fined by transplantation assays, both here (Figure 1) and
previously [13], MaSCs as being most highly enriched in
the top 5% of basal cells that most strongly express
CD49f. In contrast, Procr+ cells are found throughout
the basal CD24+ CD29+ population, not just in the cells
that most strongly express CD29 [47]. qrtPCR analysis
of Procr expression in the mammary epithelial cell sub-
populations confirmed that Procr was expressed at simi-
lar levels in both MaSCs and MYOs as well as at slightly
lower levels in luminal ER+ cells. A full gene expression
profile of the Procr+ basal cells has not been established
[47] so this cannot be used for comparison with the
MaSC signature, however, Procr+ cells were reported as
being enriched for expression of 14 EMT markers. Two
of these (Vim and Zeb2) are expressed in MaSCs.
Both Procr+ cells and MaSCs are strongly enriched for
mammary fat pad repopulation potential compared to
control populations (Procr- basal cells and MYOs, re-
spectively). The transplantation potential of the Procr+
basal population may be a result of the activity only of
those cells which fall into the top 5% of CD29-
expressing basal cells. Furthermore, the transplantation
potential of Procr+ cells was defined using transplant-
ation with Matrigel [47]; we do not use Matrigel in our
transplantation assays. Matrigel is known to improve
transplantation potential [72]. It may be that Matrigel
enhances the potential of those Procr+ cells which fall
outside the top 5% of CD29-expressing basal cells. Not-
ably, stem cell frequency of the Procr+ basal population
was calculated at one in twelve when transplanted with
Matrigel [47]; we have previously achieved nine out-
growths from thirty-four transplants when CD24+/Low
Sca-1− CD49fHigh (top 5%) c-Kit− cells were transplanted
as single cells without Matrigel [13]. In our hands, at
least, Procr expression and transplantation potential only
partially overlap but understanding the detailed relation-
ship between Procr+ basal cells and CD24+ CD49fHigh
MaSCs will require extensive lineage tracking, flow sort-
ing and transplantation studies. Nevertheless, the exact
relationship between these cell types does not affect our
findings that the gene expression signature of the cells
we have defined as MaSCs is a strong predictor of out-
come in TNBC and, therefore, defines a set of genes that
includes some that must be drivers of aggressive behav-
iour in this tumour subtype.
The basal cell population we have profiled has been
selected for its potent transplantation ability [69]. The
early events that occur following injection of single
mammary basal stem cells into a cleared fat pad are
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form outgrowths must, by definition, have the ability to
survive being reduced to single cells and introduced to a
new growth site at low density (indeed, in some experi-
ments even as single cells) [13,73] and then be able to
invade and remodel the surrounding environment, form-
ing a new tissue. The parallels with cells that can initiate
metastatic dissemination are clear, although not exact,
and we speculate that this underlies the strong associ-
ation between the MaSC gene signature (or, the ‘trans-
plantable basal stem cell gene signature’) and TNBC
with high metastatic potential.
Conclusions
We have tested the hypothesis that genes associated with
normal mouse mammary stem cells would have prognos-
tic power in human breast cancer, and we have found that
this is indeed the case. Our findings suggest that, as
tumour gene expression profiling is based on whole
tumour sampling, invasive stem cell-like potential is not
limited to a small subset of cells in aggressive TNBC.
Furthermore, we have highlighted overlaps between our
data set and those of other workers to show that the regu-
lation of cytoskeletal function is a key aspect of MaSC
biology. Finally, we have demonstrated that MaSCs have a
dual epithelial-mesenchymal identity. Our findings will
not only advance our understanding of the molecular
regulation of MaSC biology and relationship between the
biology of MaSCs and of aggressive, poor prognosis TNBC
but also have the potential to inform clinical management
of breast cancer, particularly triple-negative disease.
Additional files
Additional file 1: Purification of mouse mammary epithelial cells.
(A) Relationship between mammary epithelial population definitions
shown as sets. The size of each set as shown is not proportional to the
size of the population within the mammary gland. MaSCs, mammary
stem cells. MYOs, myoepithelial cells. (B) Full gating cascade of mouse
mammary cell preparations from initial scatter plots to gating of total
epithelium, as previously defined [18]. (C) APC vs FITC and FITC vs PE-Cy5
scatter plots of mammary cells stained with DAPI only to demonstrate
gating based on unstained controls.
Additional file 2: Primer sequences. TAQMAN Assays-on-Demand
references; primer sequences for in-house Sybr Green PCR assays; primer
sequences for single cell amplification.
Additional file 3: Single cell analysis. (A) Demonstration of linear
amplification of exogenous spike controls over two rounds of PCR.
Amplification of the three spikes proved to be linear in all samples
following PCR 1 and PCR 2 with a non-significant p-value of 1 achieved
for all seven cells across both PCR reactions using the Runs test of
linearity. This shows that amplification across three molecular values, with
a 10-fold dilution between each gene, does not differ significantly from
linearity. An analysis of covariance method was used to test if the slope
of the line, representing amplification across the three spike levels, varied
significantly between independent single cell samples. Following PCR 1
there was no significant difference in the amplification slope between
the seven samples (p = 1). Following pair wise comparison of
amplification slopes after PCR 2, a significant difference was foundbetween cell 4 and cell 7 (p = 0.049), and cell 6 and cell 7 (p = 0.028).
This suggests that a small level of variation is inherent with the second
round of PCR amplification. (B) Single cell cDNA amplification on sixteen
single and sixteen groups of ten CommaD cells. qrtPCR for seven genes
(Gapdh, Ubc, Jag1, Jag2, Wnt4, Wnt5a and Wnt10a) was performed on
the single cell and 10-cell samples and on unamplified cDNA collected
from the bulk population. The mean of sixteen single cell expression
levels for each gene was compared to the mean of expression levels
from the sixteen 10-cell samples (left hand plot). The mean single cell
amplified expression levels for the seven genes were also compared to
unamplified cDNA (right hand plot).
Additional file 4: Clinico-pathological features of the Lehmann
dataset [26].
Additional file 5: Examples of staining of single mammary cells.
(A) Single mammary cells single stained for K14, K18 and ERα. (B)
Single mammary cells (one K14+/K18- MaSC; two (weak) K14+/K18+
MaSCs; one K14-/K18+ luminal cell) sorted on to slides and double
stained for expression of K14 and K18, and counterstained with DAPI.
Bar = 10 uM.
Additional file 6: Batch analysis of raw microarray data and Procr
gene expression data. (A) Boxplot showing distribution of gene
expression in raw data sets from previous analyses [16] and the new MYO
and MaSC data sets. No evidence of a batch effect is seen. (B) qrtPCR
analysis of Procr gene expression in mammary epithelial subpopulations.
Data expressed as mean fold expression (±95% confidence intervals) over
comparator population (luminal ER- cells) in three independent isolates of
each cell population. Statistical significance was determined according to
[74]. *P <0.05, **P <0.01, N.S. not significant.
Additional file 7: Fold expression of 323 MaSC-specific genes over
myoepithelial and luminal cells ordered by fold expression relative
to myoepithelial (upper table) and luminal (lower table)
populations.
Additional file 8: Gene Ontology (GO) and Pathway analysis of
MaSC-specific genes.
Additional file 9: Top 100 genes most strongly downregulated in
MaSCs compared to MYOs.
Additional file 10: GO analysis of genes downregulated in MaSCs.
Additional file 11: Overlap of MaSC-specific genes with published
stem cell gene signatures [15-17,40,41].
Additional file 12: Table of Pearson correlations for gene
expression in MaSCs analysed at single cell resolution.
Additional file 13: Staining of basal cells for epithelial and
mesenchymal markers and heat map of MaSC signature gene
expression in Karn579 tumours ordered by DART score. (A)
Immunohistochemical staining of two representative regions of mammary
epithelium from normal mouse mammary gland for an epithelial (K14) and
two mesenchymal (SMA and Vimentin) antigens. Region 1 is an oblique
section through the edge of a duct. Bars = 10 um. Note strong staining of
basal layer for K14 and SMA, and weaker, punctate staining for Vimentin in a
subset of cells (Vimentin-positive cells within the mammary epithelium
indicated with an asterisk; the grey dashed line indicates the boundary
between the mammary epithelium and the mammary stroma, which
includes Vimentin-positive stromal cells). (B) Heat map of expression of the
323 MaSC signature genes in the Karn579 dataset ordered left to right from
high DART score tumours to low DART score tumours. Red indicates high
expression, green low expression.
Additional file 14: The MaSC gene signature performs better than
random gene lists. (A) Predictive power of 1,000 random gene sets
compared to the MaSC gene signature. The frequency of obtained
P values is shown in the y-axis, while the -log 10 P values are listed on
the x-axis. The black line indicates the P values of the 1,000 gene sets;
the P value of the MaSC signature is indicated by the red line. (B)
Averaged MaSC signature scores in tumours are correlated with
patient outcome, supporting the prognostic power of the DART score.
Additional file 15: Univariate analysis of prognostic factors in the
Karn dataset.
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qrtPCR: quantitative real-time rtPCR; RMA: robust microarray analysis;
RFS: recurrence-free survival; RT: room temperature; SAM: significance
analysis of microarrays; SMA: smooth muscle actin; TBS: Tris-buffered
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